Study Suggests Elevated Risk for Hip Fracture Among Nursing Home Residents Using Hypnotic Drug



JAMA Internal Medicine Study Highlights


Study Suggests Elevated Risk for Hip Fracture Among Nursing Home Residents Using Hypnotic Drug


A study by Sarah D. Berry, M.D., M.P.H., of Harvard Medical School, Boston and colleagues, suggests the risk for hip fracture was higher among nursing home residents who take nonbenzodiazepine hypnotic sleep medications. (Online First).


The study included 15,528 long-stay nursing home residents who were 50 years or older and who had a documented hip fracture in Medicare Part A and Part D fee-for-service claims between July 2007 and December 2008. The average age of the participants was 81 years.


There were 1,715 study participants (11 percent) who had been given a nonbenzodiazepine hypnotic drug before hip fracture. The risk for hip fracture was elevated among users of a nonbenzodiazepine hypnotic drug (odds ratio [OR], 1.66). The association between nonbenzodiazepine hypnotic drug use and hip fracture also was somewhat greater among new users (OR, 2.20) and among residents with mild vs. moderate to severe impairment in cognition (OR, 1.86 vs. 1.43), with moderate vs. total or severe functional impairment (OR, 1.71 vs. 1.16), with limited vs. full assistance required with transfers (OR, 2.02 vs. 1.43) or among those in a facility with fewer Medicaid beds (OR, 1.90), according to the study results.


“Caution should be exercised when prescribing sleep medications to nursing home residents,” the study concludes.

(JAMA Intern Med. Published online March 4, 2013. doi:10.1001/jamainternmed.2013.3795. Available pre-embargo to the media at


Editor’s Note: An author made a conflict of interest disclosure. This work was funded by grants from the National Institute on Aging and by contributions from Friends of Hebrew SeniorLife. Please see article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

ama_toc_item id=”7100″]

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email